Novo Disputes US Pick of Insulin for Drug Talks at Third Circuit

Novo Nordisk A/S is arguing before the Third Circuit that the Medicare agency unlawfully selected six of its insulin products and aggregated them as one under a government drug price negotiation program.

The Centers for Medicare & Medicaid Services rewrote the Inflation Reduction Act’s “express numerical limits” when it imposed price controls on six products and grouped them as one under the Medicare Drug Price Negotiation Program, Novo wrote Tuesday in its opening brief to the US Court of Appeals for the Third Circuit.

At issue before the court is whether the CMS violated the IRA when it imposed price ...